Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Earnings and Comprehensive Income

v3.23.2
Consolidated Statements of Earnings and Comprehensive Income - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2021
Consolidated Statements of Earnings and Comprehensive Income      
Net sales $ 1,136,702 $ 1,105,599 $ 931,032
Cost of sales 366,887 349,103 298,182
Gross margin 769,815 756,496 632,850
Operating expenses:      
Selling, general and administrative 378,378 372,766 324,951
Research and development 92,493 87,140 70,603
Total operating expenses 470,871 459,906 395,554
Operating income 298,944 296,590 237,296
Interest expense (11,215) (11,309) (13,952)
Interest income 3,410 794 473
Other non-operating income (expense), net 47,520 15,311 (75,642)
Total other income (expense), net 39,715 4,796 (89,121)
Earnings before income taxes 338,659 301,386 148,175
Income taxes (benefit) 53,217 38,287 8,590
Net earnings, including noncontrolling interest 285,442 263,099 139,585
Net earnings (loss) attributable to noncontrolling interest 179 (8,952) (825)
Net earnings attributable to Bio-Techne 285,263 272,051 140,410
Other comprehensive income (loss):      
Foreign currency translation adjustments 4,191 (32,241) 32,951
Foreign currency translation reclassified to earnings with Eminence deconsolidation 119    
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8 4,793 14,262 7,060
Other comprehensive income (loss) 9,103 (17,979) 40,011
Other comprehensive income (loss) attributable to noncontrolling interest (33) (70) 103
Other comprehensive income (loss) attributable to Bio-Techne 9,136 (17,909) 39,908
Comprehensive income attributable to Bio-Techne $ 294,399 $ 254,142 $ 180,318
Earnings per share attributable to Bio-Techne:      
Basic (in dollars per share) $ 1.81 $ 1.73 $ 0.91
Diluted (in dollars per share) $ 1.76 $ 1.66 $ 0.87
Weighted average common shares outstanding:      
Basic (in shares) 157,179 156,874 154,986
Diluted (in shares) 161,855 164,114 161,932